ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TNXP Tonix Pharmaceuticals Holding Corporation

0.2016
-0.1253 (-38.33%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 21,924,081
Bid Price 0.2002
Ask Price 0.203
News (1)
Day High 0.344

Low
0.167

52 Week Range

High
4.00

Day Low 0.167
Company Name Stock Ticker Symbol Market Type
Tonix Pharmaceuticals Holding Corporation TNXP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.1253 -38.33% 0.2016 19:57:32
Open Price Low Price High Price Close Price Prev Close
0.325 0.167 0.344 0.186 0.3269
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
28,860 21,924,081 $ 0.2395496 $ 5,251,905 - 0.167 - 4.00
Last Trade Time Type Quantity Stock Price Currency
19:58:29 5 $ 0.2016 USD

Tonix Pharmaceuticals Holding Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
10.55M 58.61M - 0 -116.88M -1.99 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tonix Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TNXP Message Board. Create One! See More Posts on TNXP Message Board See More Message Board Posts

Historical TNXP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.360.36570.1670.33322051,980,906-0.1584-44.00%
1 Month0.3880.38880.1670.34836751,496,157-0.1864-48.04%
3 Months0.3920.3940.1670.33855681,375,723-0.1904-48.57%
6 Months0.7550.7550.1670.39624951,266,034-0.5534-73.30%
1 Year3.45194.000.1670.8580169889,792-3.25-94.16%
3 Years7.8029.93750.1674.238,566,419-7.60-97.42%
5 Years163.125201.250.1676.029,771,159-162.92-99.88%

Tonix Pharmaceuticals Description

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.

Your Recent History

Delayed Upgrade Clock